Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
$STX Seagate Technology Closed at $91.03, piercing through its old resistance of $87.66 and touching a high of $91.51. Despite a revenue miss, the stock surged 8.7% as analysts turned bullish on easing tariff concerns. With heavy volume (11.76M vs. avg. 4.3M) and a clear technical move, $STX is now positioned for potential continuation into the $100+ range.
$ABEO Abeona Therapeutics Ripped through its prior resistance of $5.45, closing at $6.56 after hitting a new 52-week high of $7.32. FDA approval of Zevaskyn™ is a massive fundamental catalyst, and volume exploded (18.4M vs. avg. 1.3M). This is not a random spike—it’s backed by a valuation raise to $11/share. Biotech bulls, take notice.
$WING Wingstop Now at $263.89, this high-flier broke past $241.46 resistance with authority. EPS beat by nearly 18%, and volume has surged to nearly 3x average. Technically speaking, $WING just re-entered beast mode. Momentum traders are circling for the next leg higher toward all-time highs of $433.
$NGD New Gold Inc. Closed at $3.98, breaking out over previous resistance of $3.74 with surging volume (36.5M vs. 23.9M avg). With gold sector chatter and 2025 production updates, this low-beta miner is quietly gaining institutional attention.
$RGLS Regulus Therapeutics Closed at $7.98—breaking past its $3.49 resistance after news of a buyout by Novartis. A cash deal at $7.00 seems priced in, but options traders may be sniffing upside surprise or competing bids.
Timing Your Entry: Why After-Hours Isn’t Too Late
Breakouts often accelerate momentum into the following session, especially when fueled by volume and news. Savvy traders will be eyeing these names in pre-market scans. Look for confirmation of trend continuation—ideally with price holding above the breakout level—and don’t chase blindly. Use tight stops and consider scaling in on weakness.
Bottom Line – Who’s the Most Attractive?
While each breakout has its own flavor, $ABEO stands out for the combination of strong fundamentals (FDA catalyst), technical breakout, and valuation upside. With a raised price target of $11 and biotech interest returning, $ABEO offers the most compelling near-term reward-to-risk setup.
Watch closely tomorrow—early confirmation on these breakouts could set the tone for the rest of the week.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.